About Rod D. Martin
Praise for Rod D. Martin
Book Rod to Speak
Politics & Economics
Technology & Markets
Faith & Culture
by Patrick Cox
August 8, 2017
If you live in the US or Canada, you might not know who Jim Mellon is. But in Great Britain, Mellon enjoys the kind of respect American investors had for Warren Buffet in his younger days.
Mellon is a true self-made billionaire. He has the rare combination of clear big-picture vision and the courage to take big risks based on his own calculations. His investment wins include post-Soviet petroleum plays, German real estate, robotics, and high-end collectables.
Now, Mellon has his sights set on biotech with a particular emphasis on anti-aging therapies.
Biotech and Big Data
There are other big players focused on biotech right now. IT giants Google, Microsoft, and Apple have made aggressive moves in biotech and anti-aging. Top executives in data-intensive companies, Jeff Bezos and Larry Ellison are also placing big bets on biotechnologies aimed at aging.
What is this connection between computer science and medicine? Big data.
For decades, the computer revolution has been supercharging the pace of biological discovery. Cheaper, faster microcircuits enabled tools that revealed the molecular mechanisms of life itself. The ability to sequence human genomes forced a convergence between the mathematical and biological sciences.
The amount of data in a single human genome is staggering. To understand how genes affect health, though, we need data from huge numbers of genomes. We also need to study the medical records of those whose genomes are analyzed. Proteomics and metabolomics make the task even more complex.
It’s possible, in theory, to mine that data for therapies that can prevent or cure the diseases that destroy health and life. To do so, the most advanced computer technologies will be required.
Clearly, the time is right. Across the globe, lifespans continue to increase. That’s because diseases that were once lethal can now be treated. The downside is this often prolongs suffering and increases medical costs.
But what if we could increase health spans?
The Investment Implications of a Biotech/AI Partnership
As I’ve pointed out before, healthcare is the largest economic sector by a large margin. But what if all of the biological data being generated today could be turned into superior therapies that increase health spans? The profits would be historic.
This is why the giants of tech are focusing on aging and disease. They hope to duplicate the Silicon Valley experience, when hard-charging startups beat out established giants to become giants themselves.
Jim Mellon recently joined the race when the company he co-founded, Juvenescence Limited, announced a joint venture with Insilico Medicine. The joint venture is called Juvenescence AI. It will focus on developing compounds for the treatment of aging and age-related diseases.
The press release hailed the launch as a “multimillion dollar deal.” I’m told, though, that this figure is a modest assessment.
I take Juvenescence AI seriously not just because Mellon has been right so often in the past. The computational side of the partnership, Insilico Medicine, may be the most driven company in AI today.
Helmed by AI pioneer Alex Zhavoronkov, Insilico Medicine is headquartered at the Johns Hopkins University Emerging Technology Centers in Baltimore. But the company is international and virtual. More important, it is out to win.
I lived and worked in Silicon Valley in the old days. I consulted for startups like Netscape (the company that built the modern Web) as well as a tiny startup now known as Amazon. So I know what the Valley culture was like before hungry founders amassed fortunes and bought their private jets.
I have great respect for companies like Calico, Google’s medical venture. And I’m glad they’re tackling the aging problem. But, Insilico Medicine has far more of the original Silicon Valley spirit than Calico, which recruits from traditional companies and universities.
Many of Insilico’s researchers came to be there by winning online “hackathons”. These tests were designed to find the brightest AI experts and biologists, wherever they are. Also, most of the company’s R&D facilities are offshore. That means its costs are a fraction of its US counterparts’.
The result is collaborations with Nvidia, Albert Einstein College of Medicine, Johnson & Johnson, L’Oreal, Novartis and others.
The core mission of Insilico Medicine is the development anti-aging therapies. NVIDIA recently honored the company as one of the top five companies with the greatest potential to positively impact human wellbeing.
CEO Zhavoronkov knows he’s in a race with companies backed by tech’s deep pockets. He’s told me he must deliver a lot more bang for the buck if he’s going to win the anti-aging race. His entire company exudes a dedication to mission I haven’t seen in Silicon Valley for a very long time.
The tools employed by Insilico Medicine are deep-learning neural networks that mimic human thought processes. These algorithms, run on supercomputers, analyze data too massive for human minds to comprehend.
Already, the company has identified dozens of compounds with potential to modify biological pathways involved in aging.
Generative Adversarial Networks Are a Game-Changer
Zhavoronkov is very excited about Generative Adversarial Networks (GANs). GANs are neural networks capable of creation. GANs synthesize output based on specifications set by the programmer. You’ve probably heard about the GAN than can generate images of paintings in the style of specific artists based on user-provided descriptions.
One type of GAN is the generative hea (AAE). AAEs can be trained to create content to satisfy the programmer’s rules. Imagine an AI that can be instructed to produce a set of molecules that prevent the deterioration of nerve cells in patients at risk for dementia.
AAEs can also predict adverse effects of a drug. AAEs can also evaluate the probability of a drug passing human clinical trials. Insilico Medicine has demonstrated the first proof of concept of AAEs in oncology.
AAEs have the potential to disrupt the entire drug development field. Once we know how a drug works, the program could be tasked with finding another compound that can bring about the same molecular changes.
This breakthrough has huge implications. For the first time, the potential exists to quickly reverse engineer drugs without violating their patents. While this may scare big drug companies, it’s good news for AI startups like Juvenescence AI and healthcare consumers.
Juvenescence AI will help improve Insilico Medicine’s AIs in return for the right to choose the best of its discoveries. According to Juvenescence CEO Jim Mellon and COO Alex Picket, among those candidates is at least one compound that appears to be a true anti-aging compound.
We live in interesting times.
— Is Jim Mellon the Bill Gates of Biotech? originally appeared at Transformational Technologies.
Rod is one of our nation’s leading minds. He’s smart, original, and very committed—a combination that one rarely finds.
Rod Martin and [former Howard Dean campaign manager] Joe Trippi are America’s two foremost experts on online politics.
Rod Martin is a Reaganite-Thatcherite conservative…[and] a man who has spent much of his life ministering to and working for the benefit of others. I know Rod as an advocate for freedom, a leader who understands the real changes we need in Washington, and who has the drive and ability to make those changes happen.
Rod Martin is the kind of dynamic leader who has the knowledge, ability and experience to lead us successfully into the 21st Century. His vision for America is compelling.
Rod Martin literally wrote the book on excellence. Humble yet brilliant, a man of love and compassion, with penetrating clarity he illuminates the world around us, and we are both stirred and enlightened.
Rod Martin is a born leader and an outstanding political mind. Anyone who takes him on is going to have a serious fight on their hands.
Rod Martin is a man of uncommon vision and character. Ever since I first worked alongside Rod in the early days of PayPal, I’ve been struck by his powerful vision for the future. Rod understands the intersection of technology, politics and culture in a way that few others do.
Rod Martin wears with uncommon grace an uncanny ability to link his vigorous faith to the practical challenges of both the business world and the political arena. Yet the respect he shows for others carries a warmth and modesty that are both too rare among those who are strong advocates of feisty positions.
America badly needs more leaders who really get the future. We need more Rod Martins.
Rod Martin is a modern day philosopher-statesman. He is a capitalist intellectual, a conservative iconoclast, a gentle adversary and a kind prophet. He inspires us towards a fresh national vision built upon the original founding principles.
Rod Martin is not only effective and efficient, but he is also perceptive, wise and gracious. He gets things done. He is a great friend and a great ally.
Rod is one of the sharpest, most gracious men I know, and one of the most gifted political thinkers today. His ability to analyze issues and communicate thoughtful insights on them have earned him the respect of people across the political spectrum.
I am proud to have been Rod Martin’s friend for a quarter century, and I can tell you that he is one of the finest men and most outstanding leaders in our church and in our country today. He has a knack for turning everything he touches to success.
Rod Martin is a cornucopian entrepreneur and eutropic thinker whose influence radiates through an array of companies, institutions, movements and churches. A renaissance American, he is also a prolific friend of freedom and faith around the globe.
If Rod Martin represents the next generation of leaders, America has nothing to worry about.
A leader and a servant, in public life and in private, Rod Martin strides at the top of his profession, and has nowhere to go but up. He is in the truest sense of the word ‘outstanding’.
Rod Martin is undoubtedly one of the most accomplished thought leaders today. He is a wonderful mentor, a humble role model, and a deep inspiration for the next generation of scientific innovators and entrepreneurs.
Rod’s achievements pale beside his character and his brilliance. He sees what others can’t. He leads when others won’t.
Rod Martin is one of America’s finest young minds.
